BRAF and metastatic melanoma: Since the BRIM-3 trial with Vemurafenib [27,67] and the BREAK-3 trial with Dabrafenib [28,68], BRAF inhibitors have shown greater benefit in improving outcomes for BRAF-mutant unresectable or metastatic melanoma patients compared to chemotherapy with dacarbazine.